Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Managing psoriasis is more than going to your doctor's appointments. Learn from experts on how to improve your self-care.

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

A new study published in Heliyon has found that people who experienced abuse, neglect, or domestic abuse during childhood ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...

Professor Ed Rainger, University of Birmingham The study is part of a wider research programme on PEPITEM and its potential ...

Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U.K.—are causing irreparable damage to people's health. This damage ...

Korea: A recent retrospective cohort study published in the Journal of the American Academy of Dermatology explored the link between biologic and nonbiologic systemic therapies for psoriasis and ...

Ontario residents 66 years and older with psoriatic disease were identified, and 11,641 individuals who received their first systemic therapy between April, 2002, and January, 2021, were included.

Approximately 60% to 85% of patients who develop psoriatic arthritis will have first developed psoriasis. Blocking IL-23 may block other proinflammatory cytokines implicated in psoriasis.

Patients are taking part in a trial that scientists hope could ultimately lead to a cure for rheumatoid arthritis. The AuToDeCRA-2 study seeks to prove it is possible to train white blood cell ...